BioLamina

Eduardo Borer

🇮🇳 India

9.5

Reviewed: April 10, 2023

• - Gene Therapy Development
• - 12 weeks January - March 2023
• - Research Institution

The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.

Christopher Cassin

🇯🇵 Japan

5.6

Reviewed: February 20, 2024

• - Clinical Data Management
• - 8 weeks December 2023 - February 2024
• - Biotech Company

The data management services were delayed, and communication from the team was lacking. It was difficult to get updates, and when the deliverables arrived, they were not as polished as expected. The delays impacted our project timeline significantly.

Zachary Erdman

🇺🇸 United States

5.8

Reviewed: April 5, 2024

• - Biostatistical Design
• - 6 weeks February - March 2024
• - Research Institution

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Wilfred Bradtke

🇪🇸 Spain

9

Reviewed: February 4, 2024

• - Biomarker Development
• - 12 weeks October 2023 - January 2024
• - Research Institution

The biomarker development project was managed efficiently, with precise results that met our project objectives. The team's expertise in biomarker research was invaluable, and we were impressed with the quality of the deliverables.

Lydia Pfeffer-Howe

🇦🇺 Australia

9.1

Reviewed: September 5, 2024

• - Pharmacovigilance Services
• - Ongoing
• - Pharmaceutical Company

The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.

Kelly Marquardt-Nolan

🇳🇱 Netherlands

6.5

Reviewed: July 18, 2024

• - Regulatory Submission
• - 8 weeks May - July 2024
• - Pharmaceutical Company

The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.

Harry Davis

🇪🇸 Spain

8.9

Reviewed: March 3, 2023

• - Regulatory Submission
• - 6 weeks February 2023
• - Biotech Startup

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.

Chad Effertz

🇹🇷 Turkey

9.2

Reviewed: August 20, 2024

• - Regulatory Strategy Consulting
• - 4 weeks July - August 2024
• - Biotech Startup

The regulatory strategy consulting services were thorough and provided us with a clear pathway to regulatory approval. The team's deep understanding of the regulatory landscape was invaluable, and their strategic advice was spot on.

Ignacio Rempel

🇯🇵 Japan

6.2

Reviewed: March 15, 2024

• - Clinical Protocol Design
• - 10 weeks January - March 2024
• - Pharmaceutical Company

The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.

Henrietta Kuhlman

🇰🇷 South Korea

8.8

Reviewed: July 5, 2023

• - Biostatistical Design
• - 4 weeks May - June 2023
• - Research Institution

The biostatistical support provided was top-notch, offering clear and actionable insights that were critical to the success of our study. The team was responsive and worked closely with us to ensure the analysis met our specific needs.